Ark Invest SpaceX Purchases Hit $52.1M as Stock Nears IPO Price

Ark Invest has been buying SpaceX shares at a steady clip since the rocket company went public — and last week, the pace picked up significantly. During the week ended July 10, 2026, Cathie Wood‘s firm added roughly $52.1 million worth of SpaceX shares across its actively managed ETFs, continuing a pattern of opportunistic accumulation even as the stock slides closer to its IPO price.

Key takeaways

• Ark Invest purchased approximately $52.1 million in SpaceX shares during the week ended July 10, 2026.
• The firm spread those purchases across four ETFs: ARKK, ARKQ, ARKW, and ARKX.
• Cathie Wood projects SpaceX’s enterprise value could reach between $2.5 trillion and $3.1 trillion by 2030.
• Ark simultaneously trimmed positions in AMD, Roku, and multiple genomics companies as part of broader portfolio rebalancing ahead of Q2 earnings season.
• SpaceX stock has fallen roughly 7% from its June 12 debut price of $150, dipping close to its $135 IPO price.

Ark Invest Boosts SpaceX Holdings by $52.1 Million

The timing is deliberate. SpaceX shares have been under pressure since debuting on Nasdaq on June 12 at $150 — a blockbuster listing that briefly made Elon Musk the world’s first trillionaire. By mid-July, the stock had lost roughly 7% from that opening trade and was sinking toward its $135 IPO price, shedding 4.51% on Friday and another 4.24% the following Monday. That kind of slide is exactly what Ark has been waiting for.

According to Ark’s weekly trading disclosures, SpaceX received the firm’s largest allocation by value across its fund lineup during the week ended July 10. This follows a similar move last month, when Ark purchased around $32.5 million in SpaceX shares after the stock dropped more than 16% from its post-IPO peak — itself coming on the heels of a much larger $444.3 million investment made across four ETFs on the day of SpaceX’s Nasdaq debut.

Distribution of SpaceX shares across Ark ETFs

The latest purchases were distributed across ARKK, ARKQ, ARKW, and ARKX — a spread that reflects Ark’s view of SpaceX as relevant to multiple investment themes simultaneously: innovation, autonomous technology, space exploration, and next-generation internet infrastructure. Ark had already held SpaceX exposure before the IPO through the ARK Venture Fund, where the aerospace company was the fund’s largest holding.

It’s worth noting that Ark operates under an internal policy capping any single holding at no more than 10% of a portfolio. As share prices shift, the firm periodically rebalances to keep weightings within target allocations — meaning continued buying in a falling stock can reflect both conviction and mechanical portfolio management at the same time.

Broader Portfolio Rebalancing and Other Investments

SpaceX wasn’t the only name Ark was adding. The firm also bought shares in Coinbase Global, Circle Internet Group, Eli Lilly, Meta Platforms, and X-Energy, alongside a range of healthcare, AI, and defense-related companies. Across individual funds, fresh purchases were recorded in Block, Kratos Defense & Security Solutions, Oklo, Pony AI, Kodiak AI, and WeRide. On the healthcare side, Ark increased positions in Ionis Pharmaceuticals, Beam Therapeutics, Prime Medicine, Alamar Biosciences, Compass Pathways, and Recursion Pharmaceuticals.

New positions added in AI, healthcare, and defense

The breadth of buying reflects a deliberate tilt toward emerging and high-growth categories. X-Energy, the nuclear energy startup, appeared across three separate ETFs — a signal that Ark is treating energy infrastructure as increasingly tied to the AI buildout narrative. The pattern also echoes buying behavior seen in late June, when Ark added to Coinbase, Circle, Bullish, and Robinhood after all four stocks fell during the same trading session.

Reductions in semiconductor, streaming, and genomics holdings

On the sell side, Ark trimmed holdings in Advanced Micro Devices, Roku, Robinhood Markets, Deere, and Iridium Communications. The firm also cut positions in a string of genomics companies — Natera, Illumina, Twist Bioscience, 10x Genomics, and BioNTech — alongside smaller reductions in Personalis, Absci, and Strata Critical Medical. The genomics sell-off is notable given how central that sector once was to Ark’s identity, suggesting a meaningful rotation in the firm’s conviction priorities.

All of this is happening just ahead of the second-quarter earnings season, which adds a layer of strategic context. Ahead of earnings, active managers often adjust exposure to reduce risk in areas where results might disappoint while leaning into names where the long-term thesis is intact regardless of short-term numbers.

Cathie Wood’s Valuation Outlook on SpaceX

Cathie Wood has been vocal about why SpaceX warrants such aggressive accumulation. Speaking to Fox Business, she argued that SpaceX holds a “10-year lead” over any meaningful competitor — a claim that encompasses not just rocket launches but Starlink’s satellite internet dominance, the Starship development program, and the sheer scale of vertical integration the company has achieved.

Ark’s internal enterprise value models for 2030

Ark’s internal valuation models put the base-case enterprise value for SpaceX at approximately $2.5 trillion by 2030, with a bull-case scenario reaching around $3.1 trillion. Against a stock currently trading near its $135 IPO price — and well below the enthusiasm that greeted its June 12 debut — those projections imply a long runway of appreciation that Ark believes is still largely unpriced by the market.

That conviction gap is the core of what Ark is doing here. Every dip becomes a lower-cost entry point into a position the firm intends to hold for years. The post-IPO volatility that is making some investors nervous is, in Ark’s framework, a feature rather than a flaw — a window to accumulate before the broader market catches up to the scale of what SpaceX is building.

The FAA’s decision to close its investigation into SpaceX’s Starship booster mishap from May, clearing the path for Flight 13 with a launch window opening July 17, adds an operational catalyst that could shift near-term sentiment. Whether that’s enough to arrest the stock’s slide is another question — but Ark’s buying suggests the firm isn’t waiting for a clean chart to make its move.

FAQ

How much did Ark Invest recently spend on SpaceX shares?

Ark Invest purchased about $52.1 million worth of SpaceX shares during the week ended July 10, 2026.

Which Ark Invest ETFs hold the increased SpaceX shares?

Ark Invest increased SpaceX holdings across the ARKK, ARKQ, ARKW, and ARKX ETFs.

What other companies did Ark Invest add to its portfolio recently?

Ark Invest bought shares in Coinbase Global, Circle Internet Group, Eli Lilly, Meta Platforms, X-Energy, and several artificial intelligence, healthcare, and defense-related companies.

What is Cathie Wood’s outlook on SpaceX’s competitive position and value?

Cathie Wood stated SpaceX has a 10-year lead over competitors, with Ark’s internal models projecting a base-case enterprise value of $2.5 trillion and a bull-case estimate of $3.1 trillion by 2030.

Article produced with the assistance of artificial intelligence and reviewed by the editorial team.